June 20, 2007New England Journal of Medicine466 citations

Injectable Paromomycin for Visceral Leishmaniasis in India

SSShyam SundarNIMS University TJT. K. JhaBalaji Utthan Sansthan CTChandreshwar Prasad ThakurBalaji Utthan Sansthan

Key Points

Key points are not available for this paper at this time.

Abstract

Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India. (ClinicalTrials.gov number, NCT00216346.)

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Sundar et al. (2007) studied this question.

synapsesocial.com/papers/69d8ad33d2f7327e70ae3eb2 https://doi.org/10.1056/nejmoa066536

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral Leishmaniasis1997 · 117 citations
2Fulminant hepatitis in Kala-azar1995 · 13 citations
3A Teratological Study of Aminoglycoside Antibiotic Treatment During Pregnancy2000 · 69 citations
4Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first line drug? An observational study of 80 cases1998 · 104 citations
5Rapid, Noninvasive Diagnosis of Visceral Leishmaniasis in India: Comparison of Two Immunochromatographic Strip Tests for Detection of Anti-K39 Antibody2006 · 103 citations

Demander à l'IA

Bookmark

View Full Paper